A small biotech company faced significant challenges expressing and purifying a complex protein, which was only producible as inclusion bodies (IBs) in E. coli. With limited data on the protein’s mechanism or mode of action, they required a partner to drive development.

A very early-stage biotech company with limited funding needed to build a solid data package to attract investor interest. While initial protein expression had been done, a properly cell line and scalable process were essential for moving forward.

An established virtual biotech with a growing pipeline needed an agile R&D partner to provide wet-lab capabilities and scientific expertise. Without in-house labs, they relied on Bioneer for flexible, on-demand development support across multiple programs.

A small biotech struggled with product instability during manufacturing at a large CMO, which couldn't establish a suitable buffer exchange for lyophilization. Bioneer quickly developed and implemented a TFF process, enabling successful stabilization, lyophilization, and fill-finish.